Last reviewed · How we verify
YJP-14
At a glance
| Generic name | YJP-14 |
|---|---|
| Also known as | An 50% ethanolic extract of Lindera obtusiloba stems |
| Sponsor | Han Wha Pharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YJP-14 CI brief — competitive landscape report
- YJP-14 updates RSS · CI watch RSS
- Han Wha Pharma Co., Ltd. portfolio CI